Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

Ximelagatran (Exanta): Alternative to Warfarin?(Pharmacology Notes) (Drug Overview)

For decades, the standards of antithrombotic therapy have been heparin and coumarin compounds, primarily warfarin (1). Other newer approaches include low-molecular-weight heparins, fondaparinux, lepirudin, argatroban, and melagatran (investigational). Although existing treatments are effective, they have many limitations. A safer, more convenient therapy is needed. Ximelagatran is the first oral treatment in a new World Health […]

Darbepoetin Alfa (Aranesp) (Pharmacology Notes) (Drug Overview)

Darbepoetin Alfa (Aranesp) (Pharmacology Notes) (Drug Overview)

The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia […]

Postoperative Glycemic Control in Cardiac Surgery Patients (Pharmacology Notes) (Report)

Postoperative Glycemic Control in Cardiac Surgery Patients (Pharmacology Notes) (Report)

Blood glucose management in critically ill patients remains an ongoing controversy. In recent years, clinical trials evaluating blood glucose control in critically ill patients advocated for intense blood glucose management, with target blood glucose levels between 80 and 110 mg/dL (1). Intense blood glucose control resulted in a reduction in morbidity and mortality in the […]